Ari Raheem Zangana a and Ala Ismail Shakur b

a Department of Surgery, College of Medicine, University of Sulaimani, Kurdistan Region, Iraq. 
b Ashty Hospital, Soran.

Submitted: 14/3/2019; Accepted: 16/2/2020; Published: 21/3/2020



Infantile Hemangiomas (IH) are the most common benign tumour during childhood. Although most of the lesions do not require any treatment, problematic IH needs some sorts of intervention. Oral propranolol by a complex mechanism of action is considered as an effective way for the treatment of IH. 


The present study was conducted to clinically evaluate the outcome of propranolol as a treatment tool for proliferating infantile hemangiomas.

Patients and Methods

In this study, 17 infants, 10 males and 7 females were included in the multicenter prospective study. All infants were in the proliferative phase. Propranolol was given at a dose of 0.5 mg/kg body weight per day in two divided doses with food for one week; then the dose increased to 1-3 mg/kg body weight according to clinical response by evaluating color, firmness, surface consistency of the lesion, depth and size ranging for a period of 4-12 months duration


Most hemangiomas have elicited gradual fading of color, followed by steadily softening and decreasing in thickness of hemangiomas. Through a total no. of 17 cases before propranolol therapy, 15 cases had bright red color and 2 cases had pale color lesions. After taking propranolol therapy, only two lesions have still retained their red color, while 14 cases had clear fading of the color to pale color, and one of the cases has gained complete disappearance of the color of hemangioma to a normal skin color


Within the limitations of this prospective study, oral propranolol at a dose of 1-3 mg/kg in divided doses started during the proliferative phase, had effective therapeutic responses. However, this still needs more studies to prove the safety and efficacy of the drug. 


Hemangioma, Infantile hemangioma, Proliferative phase, Propranolol.